Dolphin Medical Services Ltd
Incorporated in 1984, Dolphin Medical Services Ltd is in the business of diagnostics and
other allied services.[1]
- Market Cap ₹ 7.73 Cr.
- Current Price ₹ 5.12
- High / Low ₹ 5.12 / 1.98
- Stock P/E
- Book Value ₹ 6.68
- Dividend Yield 0.00 %
- ROCE -0.18 %
- ROE -0.30 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.77 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 26.4%
- Company has a low return on equity of -0.82% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.96 | 0.36 | 0.57 | 0.35 | 0.15 | 0.06 | 0.18 | 0.47 | 0.52 | 0.61 | 0.68 | 0.78 | 0.70 | |
| 1.06 | 0.39 | 0.39 | 0.33 | 0.23 | 0.20 | 0.52 | 6.24 | 0.66 | 0.69 | 0.76 | 0.78 | 0.67 | |
| Operating Profit | -0.10 | -0.03 | 0.18 | 0.02 | -0.08 | -0.14 | -0.34 | -5.77 | -0.14 | -0.08 | -0.08 | 0.00 | 0.03 |
| OPM % | -10.42% | -8.33% | 31.58% | 5.71% | -53.33% | -233.33% | -188.89% | -1,227.66% | -26.92% | -13.11% | -11.76% | 0.00% | 4.29% |
| 0.00 | 0.01 | 0.15 | 0.02 | 0.09 | -0.63 | 0.05 | 5.55 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Interest | 0.05 | 0.05 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.71 | 0.52 | 0.34 | 0.33 | 0.33 | 0.24 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.10 |
| Profit before tax | -0.86 | -0.59 | -0.07 | -0.30 | -0.33 | -1.02 | -0.36 | -0.29 | -0.17 | -0.11 | -0.10 | -0.03 | -0.03 |
| Tax % | 0.00% | -3.39% | -28.57% | -10.00% | -12.12% | -1.96% | 5.56% | 6.90% | 5.88% | 9.09% | 10.00% | 0.00% | |
| -0.86 | -0.57 | -0.05 | -0.27 | -0.30 | -1.01 | -0.39 | -0.31 | -0.19 | -0.12 | -0.10 | -0.03 | -0.01 | |
| EPS in Rs | -0.57 | -0.38 | -0.03 | -0.18 | -0.20 | -0.67 | -0.26 | -0.21 | -0.13 | -0.08 | -0.07 | -0.02 | -0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 34% |
| 3 Years: | 14% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 23% |
| TTM: | 89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 48% |
| 1 Year: | 120% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 |
| Reserves | -1.72 | -2.30 | -2.34 | -2.61 | -2.91 | -3.91 | -4.30 | -4.61 | -4.80 | -4.92 | -5.03 | -5.06 | -5.02 |
| 8.10 | 8.05 | 8.16 | 8.21 | 8.21 | 6.22 | 6.37 | 0.61 | 0.68 | 0.76 | 0.80 | 0.87 | 0.83 | |
| 0.75 | 0.74 | 0.67 | 0.65 | 0.61 | 0.58 | 0.71 | 1.23 | 1.26 | 1.23 | 1.27 | 1.17 | 1.30 | |
| Total Liabilities | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
| 11.23 | 14.50 | 10.36 | 10.03 | 9.70 | 6.79 | 6.74 | 3.00 | 2.94 | 2.87 | 2.83 | 2.76 | 6.67 | |
| CWIP | 5.93 | 2.14 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 0.31 |
| Investments | 0.52 | 0.52 | 0.52 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| 4.55 | 4.43 | 4.78 | 4.98 | 4.97 | 4.86 | 4.80 | 4.83 | 4.80 | 4.80 | 4.81 | 4.82 | 4.82 | |
| Total Assets | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.18 | 0.05 | -0.12 | -0.07 | 0.00 | 0.02 | -0.13 | 0.27 | -0.10 | -0.07 | -0.05 | -0.06 | |
| -0.17 | 0.00 | 0.01 | 0.03 | 0.00 | 1.97 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -0.01 | -0.05 | 0.11 | 0.05 | 0.00 | -1.99 | 0.15 | -0.25 | 0.07 | 0.07 | 0.05 | 0.06 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | -0.02 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 0.18 | 0.05 | -0.11 | -0.07 | 0.00 | 1.99 | -0.14 | 0.27 | -0.10 | -0.07 | -0.05 | -0.06 |
| CFO/OP | -180% | -167% | -56% | -200% | 0% | -14% | 38% | -5% | 71% | 88% | 62% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 36.50 | 36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Days Payable | 12.17 | 73.00 | 0.00 | 0.00 | 0.00 | |||||||
| Cash Conversion Cycle | 24.33 | -36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Working Capital Days | 589.32 | 1,449.86 | 1,171.84 | 2,106.57 | 4,891.00 | 11,619.17 | 3,629.72 | 986.28 | 898.46 | 771.89 | 687.06 | 645.77 |
| ROCE % | -3.69% | -2.55% | -0.05% | -0.96% | -1.56% | -1.69% | -2.02% | -1.98% | -1.45% | -0.91% | -0.83% | -0.18% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Medical Materials Consumed INR |
|
|||||||||||
| Employee Benefit Expense INR |
||||||||||||
| Gross Block of Medical & Diagnostic Equipment INR |
||||||||||||
| Revenue from Diagnostic & Allied Services INR |
||||||||||||
Documents
Announcements
-
Corrigendum To Board Meeting Outcome Held On 12Th February, 2026.
30 Mar - CFO Lakshmi Sudha Madala resigned effective 12 Feb 2026; corrigendum filed 30 Mar 2026.
-
Closure of Trading Window
30 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for quarter/year ended March 31, 2026.
-
Board Meeting Outcome for Appointment And Resignation Of Kmps And Shift In Registered Office
12 Feb - On 12 Feb 2026, appointed two directors, CS-cum-CFO; CFO resigned; authorized director/intercompany loans; office shifted.
-
Board Meeting Intimation for Appointment And Resignation Of Kmps And Shift In Registered Office
10 Feb - Board meeting 12 Feb 2026: director appointments, CFO resignation/appointments, potential unsecured loans, office shift.
-
Standalone Unaudited Financial Results For The Quarter Ended December 31, 2025
6 Feb - Unaudited results for quarter/nine months ended 31.12.2025: Q3 revenue Rs21.53L, Q3 profit Rs1.68L, 9M profit Rs5.41L
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) DMSL provides a range of tests covering Radiology and Imaging, Biochemistry, Pathology, and Microbiology, etc., to the people of the coastal region of Andhra Pradesh.
b) Additionally, it has the eye care
division called the Dolphin Nethralaya
which is a comprehensive eye care
and a laser and research centre.
c) The company has also ventured
into IT and Biotechnology and Herbal
sectors